Onadeko B O, Bamidele E O, Ekweani C N, Erabor G E
Department of Medicine, University College Hospital, Ibadan, Nigeria.
Afr J Med Med Sci. 1994 Sep;23(3):301-5.
An open multicentre clinical trial of inhaled B-agonist, salmeterol, was carried out to assess its efficacy in adult Nigerian asthmatic patients. Seventy-four patients were recruited to the trial and 64 (86.48%) completed the trials. 50mcg of inhaled salmeterol was administered to the patients twice a day over a period of 2 weeks. The patients were assessed on weekly basis, at week 1, 2 and 3 subjectively and objectively using the protocol prepared by the sponsor of the study. Salmeterol was found to reduce symptoms of asthma considerably, both at day time and at night. The patient's tolerance to exercise improved significantly. The lung function assessed using Peak Expiratory Flow Meter (PEFR) showed significant improvement. Side effects were not encountered during the duration of the study. It was conclusively shown that overall, salmeterol is effective in the management of asthma in adult Nigerian patients.
开展了一项吸入型β受体激动剂沙美特罗的开放性多中心临床试验，以评估其对成年尼日利亚哮喘患者的疗效。74名患者被纳入该试验，64名（86.48%）完成了试验。在2周的时间里，给患者每天两次吸入50微克沙美特罗。使用研究主办方制定的方案，在第1、2和3周每周对患者进行主观和客观评估。发现沙美特罗能显著减轻哮喘症状，无论是白天还是晚上。患者的运动耐量有显著改善。使用呼气峰值流量计（PEFR）评估的肺功能有显著改善。在研究期间未出现副作用。最终表明，总体而言，沙美特罗对成年尼日利亚患者的哮喘治疗有效。
